BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BioBehavioral Diagnostics Reels in $5.2 Million in Stock Sale


6/4/2012 8:41:22 AM

Philadelphia Business Journal by John George, Senior Reporter

BioBehavioral Diagnostics Co. raised $5.2 million in a private stock sale, according to documents filed with the Securities & Exchange Commission.

The Plymouth Meeting, Pa., company had developed and markets a tool —originally incorporated into a kiosk-like setup — that objectively measures brain functions to assist health-care providers diagnose attention-deficit hyperactivity disorder.

Last year, I wrote about the BioBehavioral Diagnostic’s development of a portable version of its Quotient ADHD System that is designed to take up less space in an office and be taken to different locations.

The system involves patients taking a 15- to 20-minute test designed to measure inattention, or the ability to focus; hyperactivity, the inability to sit still; and impulsivity, or acting without thinking.

Those factors are key elements used in the diagnosis of ADHD, a condition that affects nearly 10 million children, adolescents and adults in the United States.

The test consists of flashing images of stars on a screen. Patients are asked to hit the space bar when certain types of stars appear, and do nothing when other types of stars are shown. Reflectors worn on a headband and around the shins measure the results.

BioBehavioral Diagnostics is led by Byron Hewett, chairman and CEO.

The equity financing was disclosed in a filing provided to the Philadelphia Business Journal by FormsD.com.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->